Results from 3 phase 3 studies unveiled Saturday showed that investigational treatment for hyperlipidemia, evolocumab, significantly lowered low-density lipoprotein (LDL) cholesterol, that the results ...
(UPDATED) The US Food and Drug Administration (FDA) has permitted new labelling claims for evolocumab (Repatha, Amgen), making it the first PCSK9 inhibitor to be indicated for the prevention of ...
PARIS, France—Eight weeks of evolocumab (Repatha; Amgen) added to a regimen of high-intensity statins following an ACS event was safe and vastly reduced LDL cholesterol levels compared with statins ...
Discover comprehensive details about Evolocumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia Evolocumab is an ...
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, ...
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of ...
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results